A phase II study of dasatinib (BMS-354825) in subjects with chronic or advanced phase chronic myelogenous leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) who are resistant or intolerant to imatinib

Next Previous
Trial Profile

A phase II study of dasatinib (BMS-354825) in subjects with chronic or advanced phase chronic myelogenous leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (ALL) who are resistant or intolerant to imatinib

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2016

At a glance

  • Drugs Dasatinib (Primary)
  • Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 20 Dec 2006 Status change
    • 10 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top